Extracting therapeutic antibodies from biological systems requires stringent purification processes. To reduce costs and accelerate development, novel strategies are essential ...

The industry has learned how the ball bounces—now it must decide where to play next.  | While 2025 was dedicated to “understanding a little bit more about the rules of this game that we’re playing,” ...

While policy shifts and leadership shakeups at institutions like the Food and Drug Administration dominated headlines in 2025, drugmakers would do well to sift through the noise and remain focused on ...

A profound transformation is taking place in therapeutic discovery, development, and delivery.2026 will be a pivotal year for biopharma. From digital transformation to an AI revolution to more ...

ArriVent BioPharma is a cautious BUY, driven by furmonertinib's late-stage potential in uncommon EGFR-mutant NSCLC and a conservative valuation approach. AVBP's strategy targets niche EGFR ...

In 2025, biopharma layoffs showed no signs of slowing, instead rising 16% year over year. Last year was challenging across the board. In a time that was expected to usher in some sort of recovery from ...

Saudi Arabia-owned energy contractor Kent is targeting new opportunities in the Middle East and beyond after rounding off 2025 with a record backlog of projects. In an exclusive interview, Kent’s ...

Kuwait Oil Company (KOC) has awarded multiple contracts worth 208 million dinars ($676.8 million) to boost its upstream operations. Kuwait’s maximum sustainable capacity (MSC) currently stands at 2.9 ...

Enterprises are beginning to treat generative AI not as an isolated productivity tool, but as the connective layer linking business applications, data, and human judgment. Nowhere is this shift ...

Jan 5 (Reuters) - Zenas BioPharma said on Monday its experimental drug cut the risk of disease flare-ups in a late-stage study of patients with a rare immune system-related condition that can damage ...

Jan 20 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded and patented medicines.